Gamma Medica to Present at 2017 TPP Healthcare China Partnering Forum; in Conjunction with Biotech Showcase alongside JP Morgan Healthcare Conference
Forum aligns global investors and CEOs
SAN FRANCISCO–(BUSINESS WIRE)–Gamma Medica, Inc.
WHO: |
Philip Croxford, President and CEO of Gamma
Editor’s Note: 1:1 interviews with Phil Croxford |
|||
WHAT: |
Mr. Croxford will be discussing the clinical advantages and |
|||
WHEN: |
Panel Therapeutic Area: Women’s health: Monday, January 9, 2017;
Panel Therapeutic Area: Cancer Diagnostics: Tuesday, January 10, |
|||
WHERE: |
Hilton Hotel, 55 Cyril Magnin St., San Francisco, CA 94102 Room Embarcadero, 3rd floor, Parc 55 |
|||
WHY: |
Gamma Medica recently announced growth across the U.S., with
|
About Gamma Medica, Inc.
Gamma Medica, Inc. is a women’s
health company focused on overcoming the limitations of anatomical
imaging experienced by mammography and other screening modalities in the
early detection of breast cancer, with women who have dense breast
tissue. The company’s LumaGEM® MBI system is the first commercially
available, FDA-cleared, fully solid-state digital imaging system
utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™)
technology for molecular breast imaging. With over 90 percent
sensitivity and specificity, LumaGEM MBI has been shown to significantly
improve cancer detection in women with dense breast tissue with fewer
false positives relative to anatomical imaging technologies, such as MRI
and whole breast ultrasound. For more information, visit, www.gammamedica.com
Contacts
Racepoint Global
Tara Kadioglu, 617-624-3239
gammamedica@racepointglobal.com